Latest News and Press Releases

Ottawa, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The global epinephrine market size was valued at USD 3.11 billion in 2024 and is predicted to hit around USD 6.39 billion by 2033, a study published by...

Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.

Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Epinephrine Autoinjectors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...

Dublin, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injection Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Epinephrine...

Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.

Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The global epinephrine market size was valued at USD 1.75 billion in 2022 and it is set to expand from USD 1.92 billion in 2023 to USD 4.08 billion by...

Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Epinephrine Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global epinephrine market is expected to grow...

Washington, DC, Oct. 26, 2023 (GLOBE NEWSWIRE) -- This week, the Asthma and Allergy Foundation of America (AAFA) is proud to join the unwavering advocacy efforts of Angel and George Mueller, parents...

Pune, India, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The global epinephrine market size was valued at USD 1.60 billion in 2021, and it is projected to grow from USD 1.75 billion in 2022 to USD 3.63...